ATE482704T1 - Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben - Google Patents

Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben

Info

Publication number
ATE482704T1
ATE482704T1 AT03808679T AT03808679T ATE482704T1 AT E482704 T1 ATE482704 T1 AT E482704T1 AT 03808679 T AT03808679 T AT 03808679T AT 03808679 T AT03808679 T AT 03808679T AT E482704 T1 ATE482704 T1 AT E482704T1
Authority
AT
Austria
Prior art keywords
receptor agonists
warts
scars
soles
dopamine receptor
Prior art date
Application number
AT03808679T
Other languages
English (en)
Inventor
Rudolf Wank
Original Assignee
Rudolf Wank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Wank filed Critical Rudolf Wank
Application granted granted Critical
Publication of ATE482704T1 publication Critical patent/ATE482704T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03808679T 2002-07-01 2003-06-27 Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben ATE482704T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10229456A DE10229456A1 (de) 2002-07-01 2002-07-01 Verwendung von Dopamin-Rezeptor-Agonisten zur Behandlung von Hautgeschwülsten und Warzen
PCT/EP2003/006851 WO2004035055A1 (de) 2002-07-01 2003-06-27 Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben

Publications (1)

Publication Number Publication Date
ATE482704T1 true ATE482704T1 (de) 2010-10-15

Family

ID=30009772

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03808679T ATE482704T1 (de) 2002-07-01 2003-06-27 Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben

Country Status (5)

Country Link
EP (1) EP1517691B1 (de)
AT (1) ATE482704T1 (de)
AU (1) AU2003301234A1 (de)
DE (2) DE10229456A1 (de)
WO (1) WO2004035055A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396982T1 (de) * 2003-11-20 2008-06-15 Lilly Co Eli Phenylfuranverbindungen als modulatoren des vitamin-d-rezeptors
US20120070518A1 (en) * 2004-01-12 2012-03-22 Natrogen Therapeutics International, Inc. Methods and compositions for treating psoriasis
DE102010032049A1 (de) * 2010-07-23 2012-01-26 Christof Plothe Homöopathische Salbe, Verfahren zu deren Herstellung und deren Verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978332A (en) * 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
IT1269634B (it) * 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
ATE243513T1 (de) * 1996-05-01 2003-07-15 Gen Hospital Corp Wachstumshemmung und abtoetung solider tumore unter verwendung eines prolaktin-modulators und eines photosensitizers
BR9908713A (pt) * 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos

Also Published As

Publication number Publication date
EP1517691A1 (de) 2005-03-30
EP1517691B1 (de) 2010-09-29
DE10229456A1 (de) 2004-02-05
DE50313136D1 (de) 2010-11-11
WO2004035055A1 (de) 2004-04-29
AU2003301234A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
WO2005034843A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE405564T1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
DE50310516D1 (de) Fredericamycin-derivate
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
RU94022017A (ru) Способ лечения акне или псевдофолликулита бороды, способ получения композиции, применение ингибитора фермента орнитиндекарбоксилазы для лечения акне или псевдофолликулита бороды
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
NO20060912L (no) Preoperativ behandling for postoperativ smerte
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE482704T1 (de) Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben
DE60214207D1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
DE602006019842D1 (de) Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
ATE418977T1 (de) Verwendung von phenylacetylderivaten zur herstellung eines arzneimittels zur behandlung der von-hippel-lindau-erkrankung